SGLT2 inhibitors

Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.

Highlights

06-07-2022 | ADA 2022 | Conference coverage | News

ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

03-02-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

» A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
» SGLT2 inhibitors: Key evidence and implications for clinical practice
» Translating SGLT2 inhibitor cardiovascular evidence into practice
» This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

Medicine Matters Diabetes

SGLT2 inhibitors

Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.

Highlights

ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

More on SGLT2 inhibitors

SGLT1/2 inhibitor shows early promise in NASH

Real-world data confirm SGLT2 inhibitor renoprotection in type 2 diabetes

Case series suggests SGLT2 inhibitors could be useful add-on therapy for MODY3

Heart failure benefits seen with first-line SGLT2 inhibition

Pros and cons with empagliflozin addition to closed-loop insulin

Frailest HF patients may stand to gain most from dapagliflozin